RNS Number : 7820L
Fusion Antibodies PLC
16 December 2025

16 December 2025

Fusion Antibodies plc
("Fusion" or the **"Company")**

Launch of the OptiMAL® Human Antibody Discovery platform

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the official launch of the OptiMAL® platform for the discovery of novel human antibodies. The OptiMAL® platform incorporates the Company's naïve, synthetic library of antibody sequences and the Mammalian Display used to select individual antibodies from the Library against a target of interest. As has been previously announced by the Company, the OptiMAL® library and the method for designing the Library are protected under US patent no. US12378696 and patents pending in other territories.

The official launch of the OptiMAL® platform took place at the Antibody Engineering and Therapeutics conference in San Diego with a speaker presentation by Dr. Richard Buick, CSO, followed by poster presentations and an exhibit booth. CEO Adrian Kinkaid also attended the official launch of OptiMAL®.

Richard Buick, CSO of Fusion, said: *"I am delighted to see the culmination of several years' work presented to an audience of antibody industry peers and look forward to the future of using this technology to bring more human therapeutic antibodies to the market."*

Enquiries:

Investor questions on this announcement

We encourage all investors to share questions on this announcement via our investor hub — Investor hub

Fusion Antibodies plc — www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer — Via Walbrook PR
Stephen Smyth, Chief Financial Officer

Allenby Capital Limited — Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance)
Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)

Shard Capital Partners LLP

Damon Heath (Joint Broker) — Tel: +44 (0) 207 186 9952

Walbrook PR — Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy — Mob: +44 (0)7876 741 001

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx ^{TM} platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFFEFFMEISESE